PE20041024A1 - Sistema de liberacion controlada - Google Patents

Sistema de liberacion controlada

Info

Publication number
PE20041024A1
PE20041024A1 PE2004000292A PE2004000292A PE20041024A1 PE 20041024 A1 PE20041024 A1 PE 20041024A1 PE 2004000292 A PE2004000292 A PE 2004000292A PE 2004000292 A PE2004000292 A PE 2004000292A PE 20041024 A1 PE20041024 A1 PE 20041024A1
Authority
PE
Peru
Prior art keywords
solvent
controlled release
alcohol
release system
codisolvent
Prior art date
Application number
PE2004000292A
Other languages
English (en)
Inventor
Kristine Fraatz
Dirk Mertin
Iris Heep
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20041024A1 publication Critical patent/PE20041024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN MEDICAMENTO, QUE COMPRENDE: 1)UN COMPONENTE FARMACEUTICO ACTIVO, QUE PUEDE SER FLUOROQUINOLONA, ENROFLOXACINO, FLUPIRTINA, ENTRE OTROS; 2)80%, EN PESO, DEL TOTAL DE LA COMPOSICION, DE ACETATO ISOBUTIRATO DE SACAROSA (SAIB); 3)GLICEROLFORMAL O ISOPROPILIDENGLICEROL O UNA MEZCLA DE LOS MISMOS, COMO DISOLVENTE; Y, 4)UN ALCOHOL, FARMACEUTICAMENTE ACEPTABLE, COMO CODISOLVENTE, SELECCIONADOS DE: ETANOL, N-BUTANOL O ALCOHOL BENCILICO. LA FORMULACION DESCRITA, SE PRESENTA EN FORMA DE SOLUCIONES, PASTAS, SUSPENSION O EMULSION. EN LA APLICACION, SE DIFUNDE UNA PEQUENA CANTIDAD DE DISOLVENTE EN EL TEJIDO CIRCUNDANTE O EL LIQUIDO INTERSTICIAL Y DEJA UN DEPOSITO ALTAMENTE VISCOSO DEL QUE EL PRINCIPIO ACTIVO SE LIBERA RETARDADAMENTE
PE2004000292A 2003-03-20 2004-03-19 Sistema de liberacion controlada PE20041024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10312346A DE10312346A1 (de) 2003-03-20 2003-03-20 Kontrolliertes Freisetzungssystem

Publications (1)

Publication Number Publication Date
PE20041024A1 true PE20041024A1 (es) 2005-01-27

Family

ID=32920993

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000292A PE20041024A1 (es) 2003-03-20 2004-03-19 Sistema de liberacion controlada

Country Status (18)

Country Link
US (1) US8231903B2 (es)
EP (1) EP1608335B1 (es)
JP (1) JP4863867B2 (es)
AR (1) AR043423A1 (es)
AT (1) ATE380017T1 (es)
AU (1) AU2004222646B2 (es)
BR (1) BRPI0408555A (es)
CA (1) CA2519351C (es)
CL (1) CL2004000566A1 (es)
DE (2) DE10312346A1 (es)
ES (1) ES2297396T3 (es)
GT (1) GT200400045A (es)
MX (1) MXPA05009910A (es)
NO (1) NO20054776L (es)
NZ (1) NZ542477A (es)
PE (1) PE20041024A1 (es)
TW (1) TW200505488A (es)
WO (1) WO2004082658A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
BRPI0515372B8 (pt) * 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
WO2008143992A2 (en) * 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
WO2009075782A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
CN102131483A (zh) * 2008-02-08 2011-07-20 昌达生物科技公司 可控给药非聚合组合物
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
WO2009145674A1 (ru) * 2008-05-28 2009-12-03 Учреждение Российской Академии Наук Институт Биохимической Физики Им. Н.М. Эмануэля Ран (Ибхф Ран) Средство для повышения октанового числа бензинового автомобильного топлива
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN102764257B (zh) * 2011-10-21 2013-09-25 四川百利药业有限责任公司 一种马来酸氟吡汀缓释片剂
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN103520098A (zh) * 2013-10-30 2014-01-22 王玉万 恩诺沙星兽用长效注射剂的制备方法
CN103550148A (zh) * 2013-10-30 2014-02-05 游锡火 延胡索酸泰妙菌素长效注射剂制备方法
CN103550150B (zh) * 2013-10-30 2016-06-08 北京中农华威制药有限公司 改进的含二甲基硅油的注射剂
CN103520168A (zh) * 2013-10-30 2014-01-22 游锡火 含延胡索酸泰妙菌素的复方注射剂
CN103520099A (zh) * 2013-10-30 2014-01-22 王玉万 含有效成份为沃尼妙林的长效注射剂
CN103536531A (zh) * 2013-10-30 2014-01-29 王玉万 甲磺酸达氟沙星长效注射剂制备方法
CN103550149A (zh) * 2013-10-30 2014-02-05 游锡火 含抗寄生虫药物长效注射剂的制备技术
CN103520167A (zh) * 2013-10-30 2014-01-22 游锡火 含硫酸头孢喹诺和甲磺酸达氟沙星的长效注射剂
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US11332444B2 (en) 2018-04-25 2022-05-17 Bayer Animal Health Gmbh Method for the hydrolysis of quinolonecarboxylic esters
TWI861178B (zh) 2019-08-14 2024-11-11 法商維多奎諾公司 用於控制寄生蟲之組成物
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) * 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) * 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) * 1985-09-18 1990-05-05 Pfizer
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
ES2258495T3 (es) * 1994-04-08 2006-09-01 Qlt Usa, Inc. Composiciones de administracion liquida de farmacos.
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
EP0882049B1 (de) * 1996-02-23 2002-11-20 Bayer Ag Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo- 4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
NZ515911A (en) * 1999-06-04 2004-02-27 Alza Corp Implantable gel compositions and method of manufacture
RU2002105502A (ru) * 1999-08-03 2004-03-20 АВД.фарма ГмбХ унд Ко. КГ (DE) Применение флупиртина для облегчения болей, вызванных дегенеративными заболеваниями суставов у собак и кошек
ATE309822T1 (de) * 2000-04-19 2005-12-15 Genentech Inc Formulierungen mit verzögerter freisetzung enthaltend wachstumshormon
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
US20050031650A1 (en) * 2002-08-26 2005-02-10 Ethypharm Composition with gelling properties for the sustained delivery of bioactive substances
DE10242088A1 (de) * 2002-09-11 2004-03-25 Bayer Ag Kontrolliertes Freisetzungssystem, welches Saccharoseacetatisobutyrat enthält

Also Published As

Publication number Publication date
GT200400045A (es) 2004-10-21
TW200505488A (en) 2005-02-16
BRPI0408555A (pt) 2006-03-21
WO2004082658A1 (de) 2004-09-30
MXPA05009910A (es) 2005-11-04
NZ542477A (en) 2009-02-28
CL2004000566A1 (es) 2005-02-04
EP1608335B1 (de) 2007-12-05
DE502004005652D1 (de) 2008-01-17
AR043423A1 (es) 2005-07-27
AU2004222646B2 (en) 2010-04-29
EP1608335A1 (de) 2005-12-28
ATE380017T1 (de) 2007-12-15
DE10312346A1 (de) 2004-09-30
JP4863867B2 (ja) 2012-01-25
JP2006520346A (ja) 2006-09-07
CA2519351A1 (en) 2004-09-30
US20060034926A1 (en) 2006-02-16
AU2004222646A1 (en) 2004-09-30
ES2297396T3 (es) 2008-05-01
US20090246277A9 (en) 2009-10-01
US8231903B2 (en) 2012-07-31
NO20054776L (no) 2005-10-17
CA2519351C (en) 2012-02-07

Similar Documents

Publication Publication Date Title
Lang et al. Antitumor activity of an Artemisia annua herbal preparation and identification of active ingredients
El-Nabarawi et al. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies
JP2020502197A5 (es)
CN102510752B (zh) 含有大环内酯类免疫抑制药物的新颖的药物组合物
KR20180080189A (ko) 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
CN106794126A (zh) 局部配制品
CN109640981A (zh) 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
EP2246049A3 (en) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs
KR20190022476A (ko) 화합물의 국소 도포용 조성물
JP2023159150A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
UA119324C2 (uk) Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
BRPI0512177A (pt) formulação de liberação modificada de memantina
BR112019015596A2 (pt) Composição farmacêutica adequada para administração tópica e método para tratar ou prevenir doenças ou distúrbios dermatológicos
CA2519351A1 (en) Controlled release system
Reynoso-Moreno et al. Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis
TW200815410A (en) Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
MX2013006816A (es) Formulaciones farmaceuticas de azol para la administracion parenteral y metodos para preparar y usar las mismas como tratamiento de las enfermedades sensibles a los compuestos de azol.
CN113274343B (zh) 多元醇作为助溶剂在秋水仙碱外用组合物中的应用
CN105377262A (zh) 局限性硬皮病的局部治疗
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
ES2584534A1 (es) Formulación tópica oftálmica de bosentan
KR20210081338A (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
JP2015517518A (ja) カルシウムチャネル遮断薬の非イオン性ベシクル製剤
ES2702578T3 (es) Tratamiento de la inflamación dérmica crónica con norketotifeno
CN109641030B (zh) 用于调节阿片类戒断症状的方法和组合物

Legal Events

Date Code Title Description
FD Application declared void or lapsed